ePrints

Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling, 2026: International consensus statement on behalf of the European Society for Immunodeficiencies/European Society for Blood and Marrow Transplantation–Inborn Errors Working Party and ERN-RITA

Lookup NU author(s): Dr Zohreh Nademi, Professor Mary Slatter

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2026 American Academy of Allergy, Asthma & Immunology. Background: Inborn errors of immunity (IEI) associated with gain of function (GOF) in the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways (JAK-STAT-GOF IEI) are rare disorders characterized by immune dysregulation, autoimmunity, malignancy, and increased infection susceptibility. To date, no JAK inhibitors (JAKi) are licensed for these conditions, but they are frequently prescribed off-label, even though high-quality evidence and treatment guidelines remain limited. Objective: We developed evidence- and consensus-based recommendations for JAKi treatment in JAK-STAT-GOF IEI across all age groups on the basis of a systematic literature review and expert consensus. Methods: An international expert group conducted a systematic literature review and developed recommendations on JAKi treatment in JAK-STAT-GOF IEI using a modified Delphi approach. Recommendations were developed based on published evidence, data from an international retrospective cohort study, and patient representative input. These statements were then tested for consensus in a 2-round Delphi survey procedure in a larger, interdisciplinary expert panel. Results: Consensus- and evidence-based guidance is presented across 5 thematic areas: (1) JAKi indications/contraindications, (2) pretreatment assessment, (3) pharmacology/dosing, (4) monitoring, and (5) use in the context of hematopoietic stem cell transplantation. A total of 51 statements were established and contextualized with the available evidence. Conclusion: This consensus provides structured guidance for clinicians managing JAK-STAT-GOF IEI with JAKi. While prospective trials will further refine these strategies, this guidance represents the current international standard of care, reflecting the synthesis of clinical experience and the best available evidence.

Publication metadata

Author(s): Olbrich P, Fischer M, Deya-Martinez A, Campos-Asensio C, Neth O, Hadjadj J, Forbes Satter LR, Leiding JW, Torgerson TR, Bakhtiar S, Baris S, Badolato R, Bloomfield M, Buddingh EP, Burroughs LM, Burns S, Cooper MA, Crickx E, Ehl S, Farmand S, Freeman AF, Gonzalez-Granado LI, Hagin D, Hanitsch LG, Hanzlikova J, Hauck F, Ivorra-Cortes J, Korholz J, Lankester AC, Leahy TR, Meyts I, Milner JD, Nademi Z, Pachlopnik-Schmid J, Pergent M, Prevot J, Riviere J, Roxo-Junior P, Schutz C, Slatter MA, Soler-Palacin P, Warnatz K, Vitovcova P, Vaastert SJ, Neven B, Albert MH, Speckmann C

Publication type: Article

Publication status: Published

Journal: Journal of Allergy and Clinical Immunology

Year: 2026

Volume: 158

Issue: 2

Pages: 598-609.e5

Print publication date: 01/08/2026

Online publication date: 27/05/2026

Acceptance date: 01/05/2026

ISSN (print): 0091-6749

ISSN (electronic): 1097-6825

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.jaci.2026.05.005

DOI: 10.1016/j.jaci.2026.05.005

PubMed id: 42203177

Altmetrics

Share